

PharmaSGP publishes preliminary half-year figures for 2025

Gräfelfing, September 11, 2025 – The German OTC pharmaceutical company PharmaSGP Holding SE generated revenues of €66.0 million in the first half of 2025 based on preliminary, unaudited figures. This corresponds to a 13.0% increase in revenues compared to the previous year (€58.4 million). In the first quarter, PharmaSGP achieved revenues of €33.5 million, while revenues in the second quarter amounted to € 32.5 million. Adjusted earnings before interest, taxes, depreciation, and amortization (adjusted EBITDA) declined by 1.4% from €16.9 million to €16.7 million in the first half of 2025 compared to the same period last year. Among other reasons, this was due to higher marketing and cost of goods sold expenses, particularly in connection with the expansion of the pureSGP brand world. The resulting adjusted EBITDA margin was 25.3% (previous year: 28.9%).

For the current financial year 2025, the Management Board expects revenues in the range of €132.0 million to €138.0 million, in line with the forecast adjusted on July 11, 2025. Adjusted EBITDA is expected to be between €37.0 million and €39.0 million. This corresponds to an adjusted EBITDA margin of 26.8% to 29.5%. The forecast for the 2025 financial year continues to take into account, among other things, the ongoing high level of uncertainty in the geopolitical and global economic situation. Further developments over the course of the year and potential consequences for Germany and Europe cannot be conclusively assessed at this time.

With the planned further expansion of the pureSGP portfolio over the long term, the company expects the margin structure of the PharmaSGP Group to change accordingly in the coming years and to settle within a range of 24.0% to 26.0% (adjusted EBITDA margin).

PharmaSGP will publish its full report for the first half of 2025 on September 25, 2025.

OVERVIEW OF PRELIMINARY YEAR-ON-YEAR FIGURES

Consolidated figures (in € million)	H1 2025	H1 2024	Δ
Revenues	66.0	58.4	+13.0%
Adjusted EBITDA	16.7	16.9	-1.4%
Unadjusted EBITDA	16.5	16.8	-1.9%
Adjusted EBITDA margin	25.3%	28.9%	
Unadjusted EBITDA margin	25.1%	28.9%	

Revenues by region (in € million)	H1 2025	H1 2024	Δ
Germany	47.8	39.6	+20.6%
Italy	10.7	11.1	-3.1%
Austria	6.0	6.1	-0.9%
Other European countries	1.4	1.6	-9.4%

Revenues share by region	H1 2025	H1 2024
Germany	72%	68%
Italy	16%	19%
Austria	9%	10%
Other European countries	3%	3%

Revenues by product category (in € million)	H1 2025	H1 2024	Δ
Health Brands	64.6	56.2	+15.0%
Beauty Brands	1.3	2.1	-37.7%

CONTACT

cometis AG
 Jakob Hafer
 Phone: +49-611-20585522
 Email: ir@pharmasgp.com

ABOUT PHARMASGP HOLDING SE

PharmaSGP is a leading consumer health company with a diversified portfolio of over-the-counter (OTC) pharmaceuticals and other healthcare products that are marketed with a focus on the pharmacy distribution channel. These products are mostly based on natural active pharmaceutical ingredients with documented efficacy and few known side effects.

The Company's core brands cover chronic indications, including rheumatic pain, nerve pain and other age-related ailments. In Germany, PharmaSGP is the market leader for systemic chemical-free pain remedies with its brand families RubaXX® for rheumatic pain and Restaxil® for neuralgic pain. Furthermore, PharmaSGP also offers leading products against sexual weakness and vertigo symptoms. Since introducing the first product from the current product portfolio in 2012, PharmaSGP has successfully established its business model in other European countries, including Austria, Italy, Belgium, Spain and France. In September 2021, the product portfolio was expanded by the brands Baldriparan®, Formigran®, Spalt® and Kamol®, thus also strengthening or developing the

indications pain and sleep disorder. The sales territory was expanded to include Switzerland and Eastern Europe. In 2024, PharmaSGP generated revenues of €118.8 million at an adjusted EBITDA margin of 31.3%.

In order to further expand its competitive position, PharmaSGP plans to increase the number of indications covered by PharmaSGP's product offering, increase PharmaSGP's European footprint, and accelerate its growth strategy especially by capitalizing on selected M&A opportunities.